Great f.y.i. Get hooked here!
How are you feeling today? Keep up to date on news and stories related to healthcare here!
The study was conducted after a group of Florida residents challenged Florida’s mask-wearing mandate in June. — FOX News: Jeanette Settembre
House Speaker Nancy Pelosi revealed Friday she’s been tested for coronavirus out of an “abundance of caution” and raised concerns about the accuracy of tests at the White House that “led to” President Trump’s exposure. — FOX News: Marisa Schultz
Researchers Will Present Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination with Doravirine, and Phase 1/1b Data for MK-8507, an Investigational NNRTI for the Treatment of HIV-1 Infection Company Plans to Advance MK-8507 into Phase 2 Evaluating its Efficacy
Campaign raises awareness about importance of dog vaccination MADISON, N.J.–(BUSINESS WIRE)–$MRK #ForThemForUs–In recognition of World Rabies Day on September 28, Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth,
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.Reddy’s”) today announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera® (dimethyl fumarate)
Dr. Reddy’s announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market, HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”)
How can I tell the difference between the flu and COVID-19? — FOX News
Johnson & Johnson plans to enroll 60,000 participants in its Phase 3 trials. Dr. Anthony Fauci and other top U.S. health officials are scheduled to testify before a Senate panel today. — NYT: Top Stories
Immetas Therapeutics Announces Series A Financing to Advance Research on Inflammation Pathways in Aging and Develop Therapeutics for Cancer and Inflammatory Disease, EAST HANOVER, N.J.–(BUSINESS WIRE)–Immetas Therapeutics today announced it has raised a Series A financing of $11 million to advance research